The Global Enteral Feeding Formulas Market size is expected to reach $8.6 billion by 2028, rising at a market growth of 8.5% CAGR during the forecast period.
The practice of delivering nutrition through the gastrointestinal system is referred to as enteral feeding. The gastrointestinal system is made up of the mouth, esophagus, intestines, and stomach. The food that is swallowed through a tube is delivered to the small intestine or stomach. This method of feeding can replace all of the calories in a diet or act as a primary source of nutrition.
In situations like cancer, eating difficulties, severe illness, stroke attacks, and life-threatening injuries, nutrition is taken into consideration. The consumption of solid food or a conventional diet can be substituted with food and nourishment delivered through a tube. Especially for individuals with chronic illnesses, enteral feeding is typically administered on a doctor's prescription and with the assistance of medical personnel.
When oral supplementation has little effect on growth and nutritional condition, enteral feeding can be started. Through nasogastric tubes, gastrostomy tubes, and jejunostomy tubes, enteral feeding can be administered. Based on the care center's knowledge, the enterostomy tube selection and installation method are made. In patients who are highly motivated, nasogastric tubes are appropriate for providing short-term nutritional support. For individuals who require enteral nourishment over an extended period, gastrostomy tubes are a better option.
The increased demand for enteral nutrition formulae for older persons at home is also leading to an increase in the number of manufacturers, which will spur the enteral feeding formula market expansion. This market is also expanding as many nursing homes and home healthcare organizations prefer enteral feeding formulas for rehabilitation of post-surgery patients. as more neonatal care units develop, the market for enteral feeding formulas market will experience further growth.
There was a noticeable rise in enteral nutrition use during the COVID-19 pandemic. The market expansion was encouraged by the rapid rise of COVID-19 cases, an increase in the number of patients admitted to intensive care units (ICUs) for coronavirus infection, and severe chronic health conditions. The use of enteral nutrition formulae is also influenced by the rise in the senior population who suffer from a variety of chronic illnesses and eating disorders, such as dysphagia, diabetes, cancer, etc. Such patients' treatment in homecare settings to reduce the risk of COVID-19 infection, also promoted the use of enteral feeding.
Through oral feeding, artificial nutrients or medications are administered to the gastrointestinal tract. Parenteral feeding employs a catheter to administer nutrition or medication intravenously into the bloodstream through central or peripheral veins. Parenteral nutrition is more likely to cause difficulties than enteral nutrition. In critically sick patients who need nutrition support therapy, enteral nutrition was emphasized in the American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines as the preferred feeding method over parenteral nutrition.
The number and diversity of enteral formulas that are used across the world, have substantially risen during the past few years. Today, there are more than 1,000 enteral formulae available, and businesses are introducing new products to appeal to a wider clientele. In order to meet the demand for nutritional food mix formulas for tube-fed patients, one such example is Abbott, which in 2019 introduced the PediaSure Harvest product and Ensure Harvest, a novel blend of real-food ingredients from sources such as mango, spinach, carrot, pumpkin, and banana. The choice of an enteral nutrition formula should take into account the patient's nutritional demands, physical condition, GI function, overall health, including medical history and metabolic anomalies, and desired outcomes.
A significant discrepancy still exists between the recommendations made in the clinical practice guidelines and actual nutrition outcomes, despite the fact that there are multiple verified clinical practice guidelines available with a focus on enteral feeding of critically sick patients. Undernutrition is another widespread issue. In order to give the bare minimum of limitations for the market expansion, hospital departments currently need to increase standardization and systematic enteral nutrition training, provide full-time nutritionists for ICUs, and distribute medical resources and staff logically. These misunderstandings of the proper use of enteral feeding would negatively impact the growth of the enteral feeding formula market.
Based on end users, the enteral feeding formula market is segmented into hospitals, long-term care facilities, nursing homes, assisted living facilities, and home care agencies & hospices. The long-term care facilities garnered a significant revenue share in the enteral feeding formulas market in 2021. When considering if enteral feeding is the best option for a loved one in a nursing home, family members can easily become overwhelmed. Staff members of long-term care facilities offer daily guidance in making these choices.
On the basis of application, the enteral feeding formula market is categorized into oncology, gastrointestinal diseases, neurological disorders, diabetes, and other applications. The oncology segment garnered the maximum revenue share in the enteral feeding formulas market in 2021. Weight loss in cancer patients is a warning indication that the disease is progressing and that their time left on earth is getting shorter. As a reasonable strategy for enhancing therapeutic results, offering nutrition support for cancer patients has been suggested. Patients may get enteral nutrition (EN) as supplemental nourishment.
On the basis of stage, the enteral feeding formula market is bifurcated into adults and pediatrics. The pediatric segment procured a significant revenue share in the enteral feeding formulas market in 2021. Babies who are ill or premature might not be able to suck or swallow well enough to use a bottle or breast. The baby can get all or part of their nutrition through an enteral feeding tube. This method of providing a healthy diet is the most effective and secure. The tube can also be used to administer oral medications.
Based on product type, the enteral feeding formula market is divided into the standard formula, disease-specific, diabetic formula, renal formula, hepatic formula, pulmonary formula, other disease-specific formula, peptide-based formula, and others. The standard formula segment dominated the enteral feeding formula market in 2021 with the highest revenue share. This growth is attributed to the widespread use of standard formulas among all patient groups and the resulting cost-effectiveness. Additionally, the high preference for and suggestions by doctors for gastrostomy tube (G-tube) patients to eat regular formulas to improve children's nutrition are assisting the growth.
| Report Attribute | Details |
|---|---|
| Market size value in 2021 | USD 4.9 Billion |
| Market size forecast in 2028 | USD 8.6 Billion |
| Base Year | 2021 |
| Historical Period | 2018 to 2020 |
| Forecast Period | 2022 to 2028 |
| Revenue Growth Rate | CAGR of 8.5% from 2022 to 2028 |
| Number of Pages | 325 |
| Number of Tables | 530 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Stage, Product, End User, Application, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Based on region, the enteral feeding formula market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North American region dominated the enteral feeding formulas market with the maximum revenue share in 2021. This growth is attributed to an increase in the cases of chronic conditions like diabetes, cancer, and neurological issues take. Rising consumer understanding of the benefits of tube feeding for treating chronic health concerns in the region is also expected to drive the regional market growth.
Free Valuable Insights: Global Enteral Feeding Formulas Market size to reach USD 8.6 Billion by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Danone S.A. (Sofina Group), Nestle S.A., Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Otsuka Pharmaceutical Co., Ltd., Meiji Holdings Co., Ltd., Reckitt Benckiser Group PLC, Hormel Foods Corporation and Medline Industries, Inc.
By End User
By Application
By Stage
By Product
By Geography
The Enteral Feeding Formulas Market size is projected to reach USD 8.6 billion by 2028.
Administration of enteral feeding being easy and less expensive are driving the market in coming years, however, Unawareness about the prescription of enteral feeding in disorders restraints the growth of the market.
Abbott Laboratories, Danone S.A. (Sofina Group), Nestle S.A., Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Otsuka Pharmaceutical Co., Ltd., Meiji Holdings Co., Ltd., Reckitt Benckiser Group PLC, Hormel Foods Corporation and Medline Industries, Inc.
The Adults market acquired the highest market share in the Global Enteral Feeding Formulas Market by Stage in 2021; thereby, achieving a market value of $5.8 billion by 2028.
The Hospitals market is leading the Global Enteral Feeding Formulas Market by End User in 2021; thereby, achieving a market value of $3.1 billion by 2028.
The North America market dominated the Global Enteral Feeding Formulas Market by Region in 2021; thereby, achieving a market value of $3.1 billion by 2028.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
